Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02193139 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
A Phase 2 study of Hyperhidrosis, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
- 1
- Study location
NCT02193139: Completed Phase 2 study of Hyperhidrosis, sponsored by Watson Pharmaceuticals.
NCT02193139 is a Phase 2 study of Hyperhidrosis that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 195 participants, above the 75-participant average among 8 other Hyperhidrosis trials with a reported enrollment target (160% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02193139, a Phase 2 study of Hyperhidrosis, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
- 1
- Study location
Study Summary
This Phase 2 study is designed to evaluate multiple doses of an anticholinergic-containing medication and identify the dose or doses that may effectively reduce axillary sweating in hyperhidrotic subjects. The anticholinergic agent being studied is designated WL8713.
Primary Outcome
Change from baseline in mean (bilateral average) sweat weight at Week 6 (LOCF)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG WL8713, 6 mg
- DRUG WL8713, 12 mg
- DRUG WL8713, 18 mg
- DRUG WL8713, 24 mg
Study Locations (1)
California
- Watson Clinical Site - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
What the finished NCT02193139 record still lists
NCT02193139 is an interventional study that assigns participants to a tested intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap, above the 75-participant average among 8 other Hyperhidrosis trials with a reported enrollment target (160% higher).
The record links to 1 condition, with Hyperhidrosis appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02193139 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02193139 about?
NCT02193139 is a clinical study titled "Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis". This Phase 2 study is designed to evaluate multiple doses of an anticholinergic-containing medication and identify the dose or doses that may effectively reduce axillary sweating in hyperhidrotic subjects. The anticholinergic agent being studied is designated WL8713.
What is the current status of trial NCT02193139?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2013-12. Estimated completion is 2014-06.
What conditions does trial NCT02193139 study?
This clinical trial studies the following conditions: Hyperhidrosis.
What interventions are being tested in trial NCT02193139?
The interventions under investigation include: Placebo (DRUG), WL8713, 6 mg (DRUG), WL8713, 12 mg (DRUG), WL8713, 18 mg (DRUG), WL8713, 24 mg (DRUG).
Who is sponsoring clinical trial NCT02193139?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02193139 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperhidrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02193139's enrollment target sits among peer trials
195 1st of 8 higher than 8 of 8 other Hyperhidrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hyperhidrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
COMPLETED · Phase 2
-
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
COMPLETED · Phase 2
-
A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects
COMPLETED · Phase 2
-
An Open Label Study for Palmar Hyperhydrosis
COMPLETED · Phase 2
-
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
COMPLETED · Phase 2
-
Botulinum Toxin Therapy in Hidradenitis Suppurativa
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276922 · 195 participants · NA
Creative Arts Program to Reduce Burnout in Healthcare Professionals
- NCT04829357 · 195 participants
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
- NCT05054738 · 195 participants · NA
CRP and S&A for Inpatient Veterans
- NCT05561595 · 195 participants · NA
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia